Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

The Hidden Cost Of Drug Development!

|Includes: AMGN, AstraZeneca Group plc (AZN)

A Forbes article noted that over the past 15 years, the number of new drugs approved per big pharma company vs. the R&D expenditure for the same resulted in a very big number in dollars...upwards of close to $12B spent per drug. The data was highly variable spanning the worst at $11.7B R&D dollars per NME (new medical entity) [AstraZeneca] (NYSE:AZN), to Amgen's (NASDAQ:AMGN) $3.7B in R&D spent per NME approved. I was originally alerted to this information by Linda Pullan

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.